Progress of intravitreal anti-vascular endothelial growth factor during pregnancy
10.3760/cma.j.cn511434-20180731-00261
- VernacularTitle:孕期玻璃体腔注射抗血管内皮生长因子药物治疗研究现状
- Author:
Jimeng LAO
1
;
Jianbo MAO
;
Lijun SHEN
Author Information
1. 温州医科大学附属眼视光医院杭州院区 310020
- From:
Chinese Journal of Ocular Fundus Diseases
2020;36(4):323-326
- CountryChina
- Language:Chinese
-
Abstract:
Intravitreal anti-VEGF injection have been widely used in retinal vascular diseases and achieved good efficacy. Early pregnancy is an important period for fetal organ formation and vascular development. Studies have proved that VEGF plays an important role in maintaining the fetal and placental vascular system, and its loss or decline will affect embryonic development and lead to abortion. The use of intravitreal anti-VEGF during pregnancy is controversial, which may cause systemic side effects to the mother and fetus. This paper summarizes the literature of 23 cases on the use of anti-VEGF during pregnancy. Three cases reported loss of pregnancy with concomitant exposure to intravitreal bevacizumab, which suggested that we should be careful about the use of anti-VEGF during pregnancy and explain the possibility of ocular and systemic side effects to patients in detail. When deciding whether to use anti-VEGF, we should consider the relationship between exposure time and the critical period of vascular development and the systemic exposure of different drugs. Currently, there is a lack of large sample size studies on the use of anti-VEGF in pregnancy, and its safety needs to be further observed.
